FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/21/2026
Back to search
Official data from USPTO
KNOTBODY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
KNOTBODY
ST13
US500000079430782Class
1, 5, 42, 44
Filing
79430782
Registration
8217622
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
07/21/2026
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
06/23/2025
Registration date
04/21/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/21/2026
Last transaction
07/21/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
TRUSILO, KELLY JEAN
Law office
L70
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Maxion Therapeutics Limited
Representatives
Ben Natter Haug Partners, LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in industry and science; biochemicalspolypeptides and engineered antibodies for scientificlaboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating or G-protein-coupled receptor modulating engineered antibodiesincluding antagonists or agonists for scientificlaboratory or research purposes; ion channel modulating or G-protein-coupled receptor modulating engineered antibodiesincluding antagonists or agonists for use in the manufacture of pharmaceuticals and drugs; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for scientificlaboratory or research purposes; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientificlaboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
Class 5
Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activityincluding preparations for the prevention and treatment of painautoimmunitycardiovascular disease and cancer; drugs for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activityincluding preparations for the prevention and treatment of painautoimmunitycardiovascular disease and cancer; engineered antibodies for medical use; pharmaceuticalsdrugs and pharmaceutical preparations incorporating engineered antibodiesion channel modulating engineered antibodies including antagonists or agonistsengineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or engineered antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activityincluding those for the prevention and treatment of painautoimmunitycardiovascular disease and cancer; vaccines
Class 42
Scientific and technological services namely scientific researchanalysis and testing in the fields of pharmaceuticalsbiochemicalspolypeptidesantibodiesion channel modulating or G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; scientific and medical research laboratory services relating to the production of antibodiesion channel modulating antibodies including antagonists or agonistsantibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discoverypreclinical and clinical development of therapeutic products; informationadvisory and consultancy services in relation to all of the aforesaid
Class 44
Medical services; medical testinganalysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodiesion channel modulating antibodies including antagonists or agonistsantibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxinspharmaceuticalsdrugs and pharmaceutical preparations derived from the aforesaid; informationadvisory and consultancy services in relation to all of the aforesaid
Publications
History of USPTO decisions and trademark events.
19 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/21/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
04/21/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/03/2026
PUBO
PUBLISHED FOR OPPOSITION
03/03/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/25/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/07/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/05/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/05/2026
RFNT
REFUSAL PROCESSED BY IB
01/01/2026
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/18/2025
RFRR
REFUSAL PROCESSED BY MPU
12/18/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/12/2025
CNRT
NON-FINAL ACTION WRITTEN
11/11/2025
DOCK
ASSIGNED TO EXAMINER
11/10/2025
MAFR
APPLICATION FILING RECEIPT MAILED
08/25/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/25/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/21/2025
Continuous trademark protection
Get notified about every new filing that threatens KNOTBODY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.